Morgan Stanley’s Anebulo Pharmaceuticals ANEB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-399,404
| Closed | -$403K | – | 8295 |
|
|
2025
Q4 | $403K | Hold |
399,404
| – | – | ﹤0.01% | 5614 |
|
|
2025
Q3 | $999K | Buy |
399,404
+185
| +0% | +$435 | ﹤0.01% | 5179 |
|
|
2025
Q2 | $575K | Hold |
399,219
| – | – | ﹤0.01% | 5403 |
|
|
2025
Q1 | $519K | Sell |
399,219
-20,775
| -5% | -$30.6K | ﹤0.01% | 5311 |
|
|
2024
Q4 | $706K | Buy |
419,994
+20,775
| +5% | +$34.2K | ﹤0.01% | 5269 |
|
|
2024
Q3 | $770K | Hold |
399,219
| – | – | ﹤0.01% | 5191 |
|
|
2024
Q2 | $1.09M | Hold |
399,219
| – | – | ﹤0.01% | 4908 |
|
|
2024
Q1 | $1.15M | Sell |
399,219
-399,219
| -50% | -$1.03M | ﹤0.01% | 4884 |
|
|
2023
Q4 | $1.93M | Buy |
+798,438
| New | +$1.88M | ﹤0.01% | 4945 |
|
|
2022
Q4 | – | Sell |
-600
| Closed | -$2K | – | 7889 |
|
|
2022
Q3 | $2K | Buy |
+600
| New | +$2.13K | ﹤0.01% | 7443 |
|
|
2022
Q2 | – | Sell |
-3
| Closed | – | – | 7791 |
|
|
2022
Q1 | $0 | Buy |
3
+1
| +50% | +$7 | ﹤0.01% | 7949 |
|
|
2021
Q4 | $0 | Buy |
+2
| New | +$13 | ﹤0.01% | 7967 |
|
Morgan Stanley's ANEB Position: Q1 2026 in Review
Morgan Stanley sold out of Anebulo Pharmaceuticals (ANEB) in Q1 2026, closing a stake of 399,404 shares — an estimated $403K sold.
Morgan Stanley first reported a position in ANEB in Q4 2021 and held it in 12 quarters. The position peaked at $1.93M in Q4 2023. 0 funds tracked by Wall St. Rank hold ANEB as of Q1 2026.
- Morgan Stanley reported no remaining Anebulo Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Morgan Stanley sold 399,404 Anebulo Pharmaceuticals shares in Q1 2026, an estimated $403K.
- Morgan Stanley first reported a position in Anebulo Pharmaceuticals in Q4 2021 and held it in 12 quarters.
- Morgan Stanley's Anebulo Pharmaceuticals position peaked at $1.93M in Q4 2023.
- 0 funds tracked by Wall St. Rank held Anebulo Pharmaceuticals as of Q1 2026.
Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.